Mannatech announced that the Board of Directors appointed James Clavijo as the new Chief Financial Officer of the company.
James Clavijo brings over 25 years of experience in executive, finance, and accounting activities. He has served as CFO for biotech, medical technology, and pharmaceutical companies, including Longeveron, Guided Therapeutics, Aeterna Zentaris, and Tri-source Pharma.
Clavijo has led and advised companies with strategic plans for pharmaceutical commercialization and manufacturing, has negotiated licensing and drug development agreements, and he has advised companies with complex restructurings, mergers, acquisitions, capital market transactions, and system implementations.
As previously announced, Landen Fredrick, Mannatech’s Chief Executive Officer, has been serving as interim CFO since January 2024. Fredrick will relinquish the responsibilities to James Clavijo as he focuses on oversight of the senior executive team and the team of general managers over our international markets, driving operational excellence and executing the Company’s strategic initiatives.
SHARE THIS: